{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:37:58Z","timestamp":1791520678015,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:00:00Z","timestamp":1556841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005941","name":"Dietmar Hopp Stiftung","doi-asserted-by":"crossref","award":["1DH1813319"],"award-info":[{"award-number":["1DH1813319"]}],"id":[{"id":"10.13039\/501100005941","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13023-019-1077-6","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T15:04:30Z","timestamp":1556895870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2\u2009years of age \u2013 a multicenter retrospective study"],"prefix":"10.1186","volume":"14","author":[{"given":"Afshin","family":"Saffari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Br\u00f6sse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelheid","family":"Wiemer-Kruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wilken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Kreuzaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias K.","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis M.","family":"van Tilburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg F.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Gorenflo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Hethey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"K\u00f6lker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Merkenschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"M\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Roser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Ulrich","family":"Schlump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Serfling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Spiegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Milde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Syrbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"issue":"13","key":"1077_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"7","key":"1077_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","volume":"14","author":"P Curatolo","year":"2015","unstructured":"Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14(7):733\u201345.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1077_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","volume":"12","author":"JC Kingswood","year":"2017","unstructured":"Kingswood JC, d'Augeres GB, Belousova E, Ferreira JC, Carter T, Castellana R, et al. TuberOus SClerosis registry to increase disease awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. 2017;12(1):2.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1077_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/ana.23960","volume":"74","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013;74(5):679\u201387.","journal-title":"Ann Neurol"},{"issue":"10056","key":"1077_CR5","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153\u201363.","journal-title":"Lancet"},{"issue":"7","key":"1077_CR6","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","volume":"51","author":"CJ Chu-Shore","year":"2010","unstructured":"Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236\u201341.","journal-title":"Epilepsia"},{"issue":"4","key":"1077_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.braindev.2013.05.006","volume":"36","author":"RR Mettin","year":"2014","unstructured":"Mettin RR, Merkenschlager A, Bernhard MK, Elix H, Hirsch W, Kiess W, et al. Wide spectrum of clinical manifestations in children with tuberous sclerosis complex--follow-up of 20 children. Brain and Development. 2014;36(4):306\u201314.","journal-title":"Brain and Development"},{"key":"1077_CR8","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2147\/NDT.S91248","volume":"12","author":"JK Capal","year":"2016","unstructured":"Capal JK, Franz DN. Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy. Neuropsychiatr Dis Treat. 2016;12:2165\u201372.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"1077_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13041-016-0222-6","volume":"9","author":"SK Hwang","year":"2016","unstructured":"Hwang SK, Lee JH, Yang JE, Lim CS, Lee JA, Lee YS, et al. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation. Mol Brain. 2016;9(1):56.","journal-title":"Mol Brain"},{"issue":"9","key":"1077_CR10","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1111\/epi.14529","volume":"59","author":"S Samueli","year":"2018","unstructured":"Samueli S, Dressler A, Groppel G, Scholl T, Feucht M. Everolimus in infants with tuberous sclerosis complex-related west syndrome: first results from a single-center prospective observational study. Epilepsia. 2018;59(9):e142\u2013e6.","journal-title":"Epilepsia"},{"issue":"6","key":"1077_CR11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.ejpn.2018.06.007","volume":"22","author":"DA Krueger","year":"2018","unstructured":"Krueger DA, Capal JK, Curatolo P, Devinsky O, Ess K, Tzadok M, et al. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): multicentre clinical experience. Eur J Paediatr Neurol. 2018;22(6):1066\u2013107.","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"1077_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA. International tuberous sclerosis complex consensus G. tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):243\u201354.","journal-title":"Pediatr Neurol"},{"issue":"12","key":"1077_CR13","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1111\/echo.13015","volume":"32","author":"R Wagner","year":"2015","unstructured":"Wagner R, Riede FT, Seki H, Hornemann F, Syrbe S, Daehnert I, et al. Oral Everolimus for treatment of a Giant left ventricular Rhabdomyoma in a neonate-rapid tumor regression documented by real time 3D echocardiography. Echocardiography. 2015;32(12):1876\u20139.","journal-title":"Echocardiography"},{"key":"1077_CR14","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"NIH","year":"2017","unstructured":"NIH. Common Terminology Criteria for Adverse Events (CTCAE) 2017 Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf ."},{"issue":"268","key":"1077_CR15","doi-asserted-by":"publisher","first-page":"268ra179","DOI":"10.1126\/scitranslmed.3009892","volume":"6","author":"JB Mannick","year":"2014","unstructured":"Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1077_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1517\/17425255.1.3.447","volume":"1","author":"M Strolin Benedetti","year":"2005","unstructured":"Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol. 2005;1(3):447\u201371.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"1077_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","volume":"37","author":"SN de Wildt","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37(6):485\u2013505.","journal-title":"Clin Pharmacokinet"},{"issue":"19","key":"1077_CR18","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801\u201311.","journal-title":"N Engl J Med"},{"issue":"6","key":"1077_CR19","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ana.24523","volume":"78","author":"DN Franz","year":"2015","unstructured":"Franz DN, Agricola K, Mays M, Tudor C, Care MM, Holland-Bouley K, et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015;78(6):929\u201338.","journal-title":"Ann Neurol"},{"issue":"nov26 1","key":"1077_CR20","first-page":"bcr2014205138","volume":"2014","author":"I. Mohamed","year":"2014","unstructured":"Mohamed I, Ethier G, Goyer I, Major P, Dahdah N. Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect. BMJ Case Reports. 2014;2014:bcr2014205138.","journal-title":"Case Reports"},{"issue":"2","key":"1077_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s00246-016-1528-y","volume":"38","author":"F Aw","year":"2017","unstructured":"Aw F, Goyer I, Raboisson MJ, Boutin C, Major P, Dahdah N. Accelerated cardiac Rhabdomyoma regression with Everolimus in infants with tuberous sclerosis complex. Pediatr Cardiol. 2017;38(2):394\u2013400.","journal-title":"Pediatr Cardiol"},{"issue":"7","key":"1077_CR22","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1007\/s00246-017-1688-4","volume":"38","author":"JS Chang","year":"2017","unstructured":"Chang JS, Chiou PY, Yao SH, Chou IC, Lin CY. Regression of neonatal cardiac Rhabdomyoma in two months through low-dose Everolimus therapy: a report of three cases. Pediatr Cardiol. 2017;38(7):1478\u201384.","journal-title":"Pediatr Cardiol"},{"issue":"1","key":"1077_CR23","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1542\/peds.2011-3476","volume":"130","author":"HA Demir","year":"2012","unstructured":"Demir HA, Ekici F, Yazal Erdem A, Emir S, Tunc B. Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma. Pediatrics. 2012;130(1):e243\u20137.","journal-title":"Pediatrics"},{"issue":"4","key":"1077_CR24","doi-asserted-by":"publisher","first-page":"e1199","DOI":"10.1542\/peds.2013-3293","volume":"134","author":"C Breathnach","year":"2014","unstructured":"Breathnach C, Pears J, Franklin O, Webb D, McMahon CJ. Rapid regression of left ventricular outflow tract rhabdomyoma after sirolimus therapy. Pediatrics. 2014;134(4):e1199\u2013202.","journal-title":"Pediatrics"},{"issue":"1","key":"1077_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/tropej\/fmu056","volume":"61","author":"V Dogan","year":"2015","unstructured":"Dogan V, Yesil S, Kayali S, Beken S, Ozgur S, Ertugrul I, et al. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus. J Trop Pediatr. 2015;61(1):74\u20137.","journal-title":"J Trop Pediatr"},{"issue":"4","key":"1077_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.pediatrneurol.2015.01.004","volume":"52","author":"I Goyer","year":"2015","unstructured":"Goyer I, Dahdah N, Major P. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. Pediatr Neurol. 2015;52(4):450\u20133.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"1077_CR27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/uog.13434","volume":"45","author":"E Mlczoch","year":"2015","unstructured":"Mlczoch E, Hanslik A, Luckner D, Kitzmuller E, Prayer D, Michel-Behnke I. Prenatal diagnosis of giant cardiac rhabdomyoma in tuberous sclerosis complex: a new therapeutic option with everolimus. Ultrasound Obstet Gynecol. 2015;45(5):618\u201321.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"7","key":"1077_CR28","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1017\/S1047951114002261","volume":"25","author":"F Oztunc","year":"2015","unstructured":"Oztunc F, Atik SU, Gunes AO. Everolimus treatment of a newborn with rhabdomyoma causing severe arrhythmia. Cardiol Young. 2015;25(7):1411\u20134.","journal-title":"Cardiol Young"},{"issue":"5","key":"1077_CR29","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1017\/S1047951116000421","volume":"26","author":"M Colaneri","year":"2016","unstructured":"Colaneri M, Quarti A, Pozzi M. Everolimus-induced near-resolution of giant cardiac rhabdomyomas and large renal angiomyolipoma in a newborn with tuberous sclerosis complex. Cardiol Young. 2016;26(5):1025\u20138.","journal-title":"Cardiol Young"},{"issue":"1","key":"1077_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5152\/TurkPediatriArs.2017.4309","volume":"52","author":"S Emir","year":"2017","unstructured":"Emir S, Hacisalihoglu S, Ozyoruk D, Ekici F, Degerliyurt A, Guven A, et al. Assessment of tumors in children with tuberous sclerosis: a single centre's experience. Turk Pediatri Ars. 2017;52(1):30\u20134.","journal-title":"Turk Pediatri Ars"},{"issue":"5","key":"1077_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/ped.12816","volume":"58","author":"SG Hoshal","year":"2016","unstructured":"Hoshal SG, Samuel BP, Schneider JR, Mammen L, Vettukattil JJ. Regression of massive cardiac rhabdomyoma on everolimus therapy. Pediatr Int. 2016;58(5):397\u20139.","journal-title":"Pediatr Int"},{"issue":"5","key":"1077_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.braindev.2018.01.001","volume":"40","author":"I Kuki","year":"2018","unstructured":"Kuki I, Kawawaki H, Okazaki S, Ehara E, Yoshida Y, Kunihiro N, et al. Efficacy and safety of everolimus in patients younger than 12months with congenital subependymal giant cell astrocytoma. Brain and Development. 2018;40(5):415\u201320.","journal-title":"Brain and Development"},{"issue":"5","key":"1077_CR33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1525-1470.1999.016005406.2.x","volume":"16","author":"RJ Hirsch","year":"1999","unstructured":"Hirsch RJ, Silverberg NB, Laude T, Weinberg JM. Tuberous sclerosis associated with congenital lymphedema. Pediatr Dermatol. 1999;16(5):407\u20138.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"1077_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1046\/j.1525-1470.2003.20326_3.x","volume":"20","author":"KA Voudris","year":"2003","unstructured":"Voudris KA, Skardoutsou A, Vagiakou EA. Tuberous sclerosis and congenital lymphedema. Pediatr Dermatol. 2003;20(4):371\u20133.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"1077_CR35","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/j.1525-1470.2010.01231.x","volume":"28","author":"M Lucas","year":"2011","unstructured":"Lucas M, Andrade Y. Congenital lymphedema with tuberous sclerosis and clinical Hirschsprung disease. Pediatr Dermatol. 2011;28(2):194\u20135.","journal-title":"Pediatr Dermatol"},{"issue":"10","key":"1077_CR36","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s13312-012-0178-2","volume":"49","author":"K Sukulal","year":"2012","unstructured":"Sukulal K, Namboodiri N. Congenital lymphedema: another unique and gender specific stigmata of tuberous sclerosis? Indian Pediatr. 2012;49(10):845.","journal-title":"Indian Pediatr"},{"issue":"6","key":"1077_CR37","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/ajmg.a.36469","volume":"164A","author":"AL Geffrey","year":"2014","unstructured":"Geffrey AL, Shinnick JE, Staley BA, Boronat S, Thiele EA. Lymphedema in tuberous sclerosis complex. Am J Med Genet A. 2014;164A(6):1438\u201342.","journal-title":"Am J Med Genet A"},{"issue":"9","key":"1077_CR38","doi-asserted-by":"publisher","first-page":"NP54","DOI":"10.1177\/0883073813499969","volume":"29","author":"G Prato","year":"2014","unstructured":"Prato G, Mancardi MM, Baglietto MG, Janis S, Vercellino N, Rossi A, et al. Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with mammalian target of rapamycin inhibitors. J Child Neurol. 2014;29(9):NP54\u20137.","journal-title":"J Child Neurol"},{"issue":"8","key":"1077_CR39","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00256-015-2094-8","volume":"44","author":"S Hoshiai","year":"2015","unstructured":"Hoshiai S, Oguma E, Sato Y, Konishi T, Minami M. Congenital focal lymphedema as a diagnostic clue to tuberous sclerosis complex: report of two cases diagnosed by ultrasound. Skelet Radiol. 2015;44(8):1165\u20138.","journal-title":"Skelet Radiol"},{"issue":"5","key":"1077_CR40","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/pde.12946","volume":"33","author":"D Jenkins","year":"2016","unstructured":"Jenkins D, McCuaig C, Drolet BA, Siegel D, Adams S, Lawson JA, et al. Tuberous sclerosis complex associated with vascular anomalies or overgrowth. Pediatr Dermatol. 2016;33(5):536\u201342.","journal-title":"Pediatr Dermatol"},{"key":"1077_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.yebeh.2018.05.039","volume":"91","author":"Susanne Schubert-Bast","year":"2019","unstructured":"Schubert-Bast S, Rosenow F, Klein KM, Reif PS, Kieslich M, Strzelczyk A. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: current evidence and future perspectives. Epilepsy Behav. 2019;91:94-8.","journal-title":"Epilepsy & Behavior"},{"key":"1077_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ebcr.2015.12.001","volume":"5","author":"R Moavero","year":"2016","unstructured":"Moavero R, Marciano S, Graziola F, Curatolo P. Combined targeted treatment in early onset epilepsy associated with tuberous sclerosis. Epilepsy Behav Case Rep. 2016;5:13\u20136.","journal-title":"Epilepsy Behav Case Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1077-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T16:19:56Z","timestamp":1721233196000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1077-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1077"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1077-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]},"assertion":[{"value":"18 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics committees of the University of Heidelberg, Germany, and the University of Leipzig, Germany.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.S. received grants from Biogen.I.B. declares that she has no competing interests.A.W-K. received research funding from Novartis and Nutricia, and honoraria from Novartis, Desitin, Nutricia, Vitaflo and UCB.B.W. declares that he has no competing interests.P.K. declares that she has no competing interests.A.H. declares that he has no competing interests.M.K.B. received honoraria from PTC Therapeutics.C.v.T. participated at advisory boards of Novartis and Bayer Vital GmbH.G.F.H. declares that he has no competing interests.M.G. declares that he has no competing interests.S.H. declares that he has no competing interests.O.K. reports honoraria from Novartis.S.K. declares that he has no competing interests.O.W. declares that he has no competing interests.A.Me. declares that he has no competing interests.A.M. declares that he has no competing interests.T.R. declares that he has no competing interests.J.U.S. declares that he has no competing interests.A.Se. declares that she has no competing interests.J.S. declares that she has no competing interests.T.M. declares that he has no competing interests.A.Z. declares that he has no competing interests.S.S. received one travel grant from Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"96"}}